Literature DB >> 2565819

Role of dopamine D-1 and D-2 receptors in the regulation of neurotensin systems of the neostriatum and the nucleus accumbens.

K M Merchant1, J W Gibb, G R Hanson.   

Abstract

Activation of dopamine D-1 receptors with multiple administrations of SKF 38393 significantly increased the level of neurotensin-like immunoreactivity in the striatum and the nucleus accumbens. However, a similar treatment with the D-2 receptor-selective agonist, LY 171555, decreased the same in both structures; when the two drugs were administered concurrently, their individual effects were blocked. These results suggest that dopamine D-1 and D-2 receptors antagonistically regulate neurotensin systems of the striatum and nucleus accumbens. On the other hand, blockade of D-2 receptors (with sulpiride) elevated, while D-1 receptors blockade (with SCH 23390) caused no change in the level of neurotensin in both these structures. Dopamine D-1 receptors did not appear to contribute to the sulpiride-mediated effect as concurrent administration of SCH 23390 did not alter the response.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2565819     DOI: 10.1016/0014-2999(89)90098-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

1.  Striatal and ventral pallidum dynorphin concentrations are markedly increased in human chronic cocaine users.

Authors:  Paul S Frankel; Mario E Alburges; Lloyd Bush; Glen R Hanson; Stephen J Kish
Journal:  Neuropharmacology       Date:  2008-04-29       Impact factor: 5.250

2.  Response of limbic neurotensin systems to methamphetamine self-administration.

Authors:  G R Hanson; A J Hoonakker; M E Alburges; L M McFadden; C M Robson; P S Frankel
Journal:  Neuroscience       Date:  2012-01-02       Impact factor: 3.590

3.  Chronic, but not acute, dosing of antipsychotic drugs alters neurotensin binding in rat brain regions.

Authors:  P E Holtom; P L Needham; G W Bennett; S Aspley
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

4.  Mephedrone alters basal ganglia and limbic neurotensin systems.

Authors:  Christopher L German; Amanda H Hoonakker; Annette E Fleckenstein; Glen R Hanson
Journal:  J Neurochem       Date:  2014-04-19       Impact factor: 5.372

5.  Effect of low doses of methamphetamine on rat limbic-related neurotensin systems.

Authors:  Mario E Alburges; Amanda J Hoonakker; Nathaniel M Cordova; Christina M Robson; Lisa M McFadden; Amber L Martin; Glen R Hanson
Journal:  Synapse       Date:  2015-06-11       Impact factor: 2.562

6.  Effect of methamphetamine self-administration on neurotensin systems of the basal ganglia.

Authors:  Paul S Frankel; Amanda J Hoonakker; Mario E Alburges; Jacob W McDougall; Lisa M McFadden; Annette E Fleckenstein; Glen R Hanson
Journal:  J Pharmacol Exp Ther       Date:  2010-12-02       Impact factor: 4.030

7.  Responses of the rat basal ganglia neurotensin systems to low doses of methamphetamine.

Authors:  Mario E Alburges; Amanda J Hoonakker; Nathaniel M Cordova; Christina M Robson; Lisa M McFadden; Amber L Martin; Glen R Hanson
Journal:  Psychopharmacology (Berl)       Date:  2014-02-13       Impact factor: 4.530

8.  Differential induction of neurotensin and c-fos gene expression by typical versus atypical antipsychotics.

Authors:  K M Merchant; D M Dorsa
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

9.  Response of neurotensin basal ganglia systems during extinction of methamphetamine self-administration in rat.

Authors:  Glen R Hanson; Amanda J Hoonakker; Christina M Robson; Lisa M McFadden; Paul S Frankel; Mario E Alburges
Journal:  J Pharmacol Exp Ther       Date:  2013-05-17       Impact factor: 4.030

10.  Nicotinic and dopamine D2 receptors mediate nicotine-induced changes in ventral tegmental area neurotensin system.

Authors:  Mario E Alburges; Amanda J Hoonakker; Glen R Hanson
Journal:  Eur J Pharmacol       Date:  2007-07-24       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.